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The efficacy and tolerance of tocainide used alone and
in combination with quinidine were studied in 20 patients
with coronary artery disease and frequent (2:::30/h) ven-
tricular premature complexes. Holter electrocardio-
graphic monitoring was performed at baseline and dur-
ing therapy with tocainide alone, quinidine alone and a
combination of tocainide and quinidine. During single
drug therapy, the dose of tocainide was 1,680 ± 437
mg/day and that of quinidine was 1,340 ± 235 mg/day.
During combination therapy, with smaller doses of to-
cainide (1,350 ± 394 mg/day) and quinidine (1,060 ±
268mg/day) in many patients , no patient had side effects.
At baseline before therapy, the mean ventricular pre-
mature complexeslh were 629 ± 567, couplets/h were
23.9 ± 29.7 and nonsustained ventricular tachycardias/
24 h were 60.5 ± 152.2. Compared with baseline values
(100%), the frequency of ventricular premature com-
plexes was reduced to 33 ± 44% with quinidine, 39 ±
30% with tocainide and 10 ± 16% with combination
therapy (p < 0.01 for combination versus quinidine or
Tocainide is a lidocaine analogue that is used for long-term
oral therapy of ventricular arrhythmia. It has been used in
treatment of patients with ventricular premature complexes
(1-4) and recurrent sustained ventricular tachycardia (5-8) .
Its antiarrhythmic efficacy may be approximately that of
other antiarrhythmic agents , such as quinidine , procain-
amide and disopyramide (9,10). Its efficacy, like that of
other antiarrhythmic agents , is often limited by dose-related
side effects (8- 10). A significant number of patients develop
dose-related side effects when taking tocainide in a dosage
that achieves plasma levels adequate for arrhythmia suppres-
sion (8). When the dosage of tocainide is reduced to a
tolerable level , arrhythmias often recur (8). Because the side
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tocainide alone; p =NS for quinidine versus tocainide).
Individually, an effective regimen (>83% reduction of
ventricular premature complexes and abolition of non-
sustained ventricular tachycardia) was found in 3 (15%)
of 20 patients receiving tocainide alone, in 6 (30%) re-
ceiving quinidine alone and in 16 (80%) receiving com-
bination therapy (p < 0.01 for tocainide versus combi-
nation, quinidine versus combination; p = NS for
tocainide versus quinidine).
Thus, the antiarrhythmic effects of quinidine and to-
cainide are additive. A combination of quinidine and
tocainide in smaller and well tolerated doses may avoid
dose-related side effects and is more effective than either
drug used alone at higher doses. Therefore, when quin-
idine or tocainide is ineffective because dose-related side
effects limit the maximal tolerated dose, combination
therapy in smaller and tolerable doses may avoid side
effects and may be more effective than either drug alone
at the maximal tolerated dose.
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effects of quinidine differ from those of tocainide, a com-
bination of tocainide and quinidine in smaller and more
tolerable doses may render additive antiarrhythmic effects
without additive dose-related side effects . This was studied
in 20 patients with coronary artery disease and frequent
(2:30/h) ventricular premature complexes.
Methods
Study design. All patients had coronary artery disease
with frequent (2:30/h) ventricular premature complexes and
were referred to the arrhythmia service of our medical center
for recurrent sustained ventricular tachycardia (14 patients)
or symptomatic ventricular arrhythmia (6 patients). No pa-
tient had uncompensated congestive heart failure at the time
of entry into the study. There were 15 men and 5 women,
aged 62 ± 10 years. At least five half-lives after all anti-
arrhythmic drugs were discontinued, a baseline 24 hour
ambulatory electrocardiogram (ECG) was recorded in all
patients .
0735-1097/87/$3 .50
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Protocol. During single drug therapy with quinidine and
tocainide, the initial dosage of quinidine (1,200 to 1,600
mg/day, given every 6 hours in equally divided doses) and
tocainide (1,200 to 1,600 mg/day, given every 6 to 8 hours
in equally divided doses) was adjusted to the maximal tol-
erated dosage without side effects. To alleviate side effects,
tocainide was given with a snack (9). A 24 hour ambulatory
ECG recording was started when a patient had received
quinidine at the maximal tolerated dosage for at least five
doses and tocainide at the maximal tolerated dosage for at
least 2 days to ensure steady state blood levels. During
combination therapy with quinidine and tocainide, many
patients received less of each drug, and none received more,
than they received during single dose therapy. The dose
adjustments during combination therapy were largely em-
piric and determined by the investigators on the basis of
side effects, patients' body weight and frequency of ven-
tricular premature complexes noted on the telemetry unit
monitors. After combination therapy had been established
for at least 2 days, another ambulatory ECG was recorded.
The serum level of quinidine was obtained I hour before
the next dose of quinidine during quinidine therapy and
combination therapy. The serum concentration of tocainide
was not determined because this assay was not available in
our institution at the time of our study.
Ambulatory ECGs. Continuous 24 hour ambulatory
ECGs were recorded on an Avionics 445 two channel re-
corder. Analysis of the tape was performed on a comput-
erized Cardio Data System scanner. Total numbers of ven-
tricular premature complexes, couplets and ventricular
tachycardia (;::::3 ventricular premature complexes at a rate
> 100 beats/min) were generated by the scanner. The ac-
curacy of this system has been published (II). Mean ven-
tricular premature complexes or couplets/h were calculated
by dividing the total number of ventricular premature com-
plexes or couplets by the number of hours recorded. The
results were verified by one of us.
Statistical methods. Standard deviation (mean ± SD)
was used as the index of dispersion of observed values.
One-way analysis of variance (ANOYA), the Kruskal-Wal-
lis test or Fisher's exact test was used to compare appropriate
variables between groups. A two-tailed probability (p) value
of <0.05 was considered significant.
Results
Antiarrhythmic therapy. During single drug therapy
the dosage of tocainide was 1,680 ± 437 and that of quin-
idine was 1,340 ± 235 mg/day. The dosage of tocainide
during combination therapy was 1,350 ± 394 mg/day and
was significantly less than that during treatment with to-
cainide alone (p < 0.005). In 10 of the 20 patients, a lower
dosage of tocainide was given during combination treat-
ment. No patient received more tocainide during combi-
nation treatment. The dosage of quinidine during combi-
nation therapy was 1,060 ± 268 mg/day and was significantly
less than that during treatment with quinidine alone (p <
0.01 versus single drug therapy). A lower dosage of quin-
Table 1. Results of Ambulatory ECG in 20 Patients
Patient
Ventricular Premature Complexes/h
No. Baseline Tocainide Quinidine Combination
I 40 23 (57.5) 20 (50.0) 6.6 (16.6)
2 1,426 215 (15.1) 1,156 (81.1) 15.6 (l.l)
3 691 144 (20.8) 127 (18.4) 60.0 (8.7)
4 958 527 (55.0) 210 (21.9) 1.14 (0.1)
5 441 69 (15.6) 23 (5.2) 2.7 (0.6)
6 1,063 0.56 (0.0) 175 (16.5) 0.26 (0.0)
7 61 2.74 (4.5) 1.38 (2.2) 0.55 (0.9)
8 142 66 (46.5) 202 (142.3) 92 (64.8)
9 1,144 992 (86.7) 30 (2.6) 330 (28.8)
10 1,882 282 (0.1) 0.7 (0.0) 0.14 (0.0)
II 1,415 733 (51.8) 310 (21.9) 380 (26.9)
12 379 133 (35.1) 41 (10.8) 2.1 (0.6)
13 123 41 (33.3) 28 (22.8) 5.7 (4.6)
14 30 0(0) 4.0 (13.4) 0(0)
15 1,263 1,135 (89.9) 44 (3.5) 4 (0.3)
16 359 329 (91.6) 574 (159.9) 98 (27.3)
17 145 86 (59.3) 31 (21.4) 0.22 (0.2)
18 158 41 (25.9) 23 (14.6) 16(10.1)
19 370 205 (55.4) 107 (28.9) 17 (4.6)
20 67 25 (37.3) 15 (22.4) 2.5 (3.7)
Numbers in parentheses are percent of baseline value in each patient. Combination = combination of
quinidine and tocainide.
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Table 2. Results of Ambulatory ECG in 20 Patients
Patient
Couplets/h
No. Baseline Tocainide Quinidine Combination
I 14.64 0.04 (0.3) 0.46 n. [) 0(0)
2 7.21 0.35 (4.9) U (18.0) 1.26(17.5)
3 54.04 4.64 (8.6) 6.3 (11.7) 0.27 (0.5)
4 33.94 1.5 (4.4) 0.74 (2.2) 0.16 ro.s:
5 63.0 0.56 (09) 0.35 (0.6) 0(0)
6 5.03 0(0) O.D (2.5) 0(0)
7 2.17 0.05 12.3) 0.11 (5.1) 0(0)
8 20.13 0.46(13) 0.23(11) 0(0)
9 9.15 12.89 (140.9) 0(0) 0.10 (1.1)
10 109 o ((l) 0.14 ro.u 0(0)
II 69.0 6.7 (9.7) 13.9 (20.1) 0.7(1.0)
12 25.4 2.43 (9.6) 0.37 (1.5) 0.06 (0.2)
D 1.29 0.06 (4.7) 0.12 (9.3) 0(0)
14 0.1 0(0) 0(0) 0(0)
15 2.04 0.37 (18.1) 0.12 (5.9) 0(0)
16 44.6 31.6170.1) 48.6 (109.0) 1.18 (2.6)
17 0.6 0.06 (10.0) O.[3 (2[ .7) 0(0)
18 3.5 1.0 (28.6) 0.7 (20.0) 0.09 (2.6)
19 7.5 2.7136.0) 1.2 (16.0) 0.05 (0.7)
20 5.6 1.903.9) 1.5 (26.8) 0.1 (1.8)
Numbers in parentheses are percent of baseline value in each patient.
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idine was given in 13 patients and no patient received more
quinidine during combination treatment. None of the pa-
tients had side effects attributable to either tocainide or
quinidinewhile receivingcombination treatment. No patient
had worsening of congestive heart failure evidenced by a
new third heart sound or increased respiratory rales. Quin-
idine level was 3.41 ± 0.95 ILg/ml during single drug
therapyand 2.57 ± 0.85 ILg/ml during combination therapy
(p < 0.05).
Ambulatory ECG: group responses (Tables 1, 2 and
3). At baseline before therapy, mean ventricularpremature
cornplexes/h were 629 ± 567. couplets/hwere 23.9 ± 29.7
and episodes of nonsustained ventricular tachycardia/24 h
were60.5 ± 152.2. Meanventricularprematurecomplexesl
h were 156 ± 274/h with quinidine alone, 252 ± 336/h
with tocainide alone and 52 ± 108/h with combination
therapy (p < 0.05 for combination versus quinidine or to-
cainide; p = NS for tocainide versus quinidine). Mean
couplets/h were 3.8 ± 11.0/h with quinidine alone, 3.4 ±
7.4/h with tocainide alone and 0.20 ± 0.38/h with com-
bination therapy (p = NS for combination versus quinidine
or tocainide; quinidine versus tocainide). The number of
episodesof nonsustainedventriculartachycardiawas 4.9 ±
14.3124 h with quinidine alone, 7.4 ± 25.4124 h with to-
cainide alone and 1.1 ± 4.9/24 h with combination therapy
(p < 0.005 for tocainide versus combination; p < 0.025
for quinidine versus combination; p = NS for tocainide
versus quinidine).
Because of wide variation in frequency of ventricular
ectopic activity among individual patients at baseline. the
frequency of ventricular arrhythmias during each treatment
period was also expressed as percent of the baseline value
in each patient. Compared with the baseline value of each
patient (I00%), the frequency of ventricularprematurecom-
plexes was reduced to 33 ± 44% with quinidine alone, 39
± 30% with tocainide alone and 10 ± 16% with combi-
nationtherapy(p < 0.001 for tocainideversuscombination;
Table3. Results of Ambulatory ECG in 20 Patients
Episodes of Ventricular Tachycardial24 h
Patient No. Baseline Tocainide Quinidine Combination
I 2 0 0 0
2 28 1 2 0
-' 170 18 0 0
4 27 2 I 0
5 78 0 1 0
6 I I 0 0
7 2 2 0 0
8 4 0 0 0
9 8 0 0 0
10 55 0 0 0
I [ 680 114 35 22
12 lDO 2 2 0
13 6 0 0 0
14 I 0 0 0
15 3 0 0 0
16 31 4 56 0
17 2 0 0 0
18 6 2 1 0
19 4 1 0 0
20 I 0 0 0
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Discussion
Our study suggests that in patients with coronary artery
disease and frequent ventricular premature complexes 1) the
antiarrhythmic effects of quinidine and tocainide are addi-
tive, and 2) a combination of quinidine and tocainide in
smaller and well tolerated doses may avoid dose-related side
p < 0.01 for quinidine versus combination; p = NS for
quinidine versus tocainide). The frequency of couplets was
reduced to 14 ± 24% with quinidine alone, 19 ± 34%
with tocainide and 1.4 ± 3.9% with combination therapy
(p < 0.05 for combination versus quinidine or tocainide
alone; p = NS for quinidine versus tocainide). The fre-
quency of nonsustained ventricular tachycardias was re-
duced to 15.6 ± 30.4% with tocainide, 10.8 ± 0.2% with
quinidine and 0.16 ± 0.72% with combination therapy (p
< 0.05 for tocainide versus combination; p = NS for quin-
idine versus combination and quinidine versus tocainide).
Ambulatory ECG: individual responses (Tables 1, 2
and 3). A significant (>83%) reduction of ventricular pre-
mature complexes (12) was noted in 9 of the 20 patients on
quinidine alone, 6 on tocainide alone and 16 on combination
treatment (p < 0.005 for tocainide versus combination; p
< 0.05 for quinidine versus combination; p = NS for to-
cainide versus quinidine). Abolition of nonsustained ven-
tricular tachycardia (13) was noted in 10 patients (50%) on
tocainide, 13 (65%) on quinidine and 19 (95%) during com-
bination treatment (p < 0.005 for tocainide versus combi-
nation; p < 0.05 for quinidine versus combination; p = NS
for tocainide versus quinidine). An effective regimen de-
fined as a >83% reduction of ventricular premature com-
plexes and abolition of nonsustained ventricular tachycardia
(13-15) was found in 3 patients (15%) on tocainide, 6 (30%)
on quinidine and 16 (80%) on combination treatment (p <
0.005 for combination versus quinidine or tocainide alone;
p = NS for quinidine versus tocainide).
Twelve lead ECG (Table 4). Significant prolongation
of the QRS complex and QTc (corrected QT interval by the
Bazett formula) (16) was noted during quinidine and com-
bination therapy (p < 0.001). During tocainide therapy, no
significant changes in duration of QRS complex and QTc
interval were noted. The duration of QRS complexes and
QTc interval during combination therapy were significantly
shorter than those during quinidine alone (p < 0.05).
Table 4. ECG Intervals in 20 Patients
Baseline
Quinidine
Tocainide
Combination
PR (s)
0.17 ± 0.02
0.17 ± 0.02
0.17 ± 0.02
0.\7 ± 0.02
QRS (s)
0.095 ± 0.0\8
0.107 ± 0.0\4
0.097 ± 0.0\9
0.102 ± 0.0\5
QTc (s)
0.429 ± 0.024
0.459 ± 0.03\
0.430 ± 0.029
0.450 ± 0.237
effects and is more effective than either drug used alone at
higher doses. Therefore, when quinidine or tocainide is
ineffective because dose-related side effects limit the max-
imal tolerated dosage, combination therapy in smaller and
more tolerable dosages may be more effective than either
drug alone at maximal tolerated dosage.
Holter monitoring. A 24 hour ambulatory ECG was
used to assess the antiarrhythmic efficacy of single drug and
combination therapy in our study. Other investigators (1-
3,5,13-15,17,18) have also used a 24 hour ambulatory ECG
to assess efficacy of antiarrhythmic agents. Because of day
to day variations in the frequency of ventricular premature
complexes in individual patients, only a marked (>83%)
reduction in ventricular premature complexes can be attrib-
uted to specific antiarrhythmic agents (12,19) when com-
paring the results of one 24 hour ambulatory monitoring
during each therapy. Michelson and Morganroth (20) also
reported that a 75% reduction in the frequency of couplets
and a 65% reduction in the frequency of nonsustained ven-
tricular tachycardia would be required to demonstrate ther-
apeutic efficacy. When evaluating antiarrhythmic agents in
groups of patients, however, the spontaneous variability
becomes less important and less dramatic reductions of ven-
tricular ectopy are considered significant (19). Therefore,
comparing the results of a 24 hour ambulatory monitoring
during each treatment period in a group of 20 patients, the
day to day variations in ventricular premature complexes,
couplets and nonsustained ventricular tachycardia in indi-
vidual patients are not considered critical (19). The com-
bination therapy was more effective than single drug therapy
with quinidine or tocainide when group responses as well
as individual responses were considered.
Single drug therapy. In our study, a significant (>83%)
reduction of ventricular premature complexes was noted in
30% of patients during tocainide therapy. This rate appears
to be lower when compared with response rates of other
studies. Winkle et al. (1) reported that ventricular premature
complexes were suppressed by more than 70% in 11 (73%)
of 15 patients. Woosley et al. (2) reported that 8 (67%) of
12 patients had >75% reduction of ventricular premature
complexes. LeWinter et al. (3) reported that 5 (50%) of 10
patients had >80% reduction of ventricular premature com-
plex frequency. When a >70% reduction is considered sig-
nificant, 8 (40%) of 20 patients in our study had a significant
reduction of ventricular premature complexes and our results
are thus not significantly different from those of others (1-
3) (p = NS by Fisher's exact test). The response of our
patients to quinidine is similar to that reported by others
(21). When tocainide and quinidine were compared, quin-
idine appeared to be more effective in reducing ventricular
premature complexes and nonsustained ventricular tachy-
cardia. However, the differences between quinidine and
tocainide were not statistically significant. This finding is
similar to that of Morganroth et al. (10). The daily doses
JACC Vol. 9, No.6
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of tocainide and quinidine in our study were similar to those
of others (9,10). These findings suggest that our patient
population and study methods were not significantly dif-
ferent from those of other studies (1-3,9, 10,21) .
Other investigators (9) administered a snack with to-
cainide, as we did, to avert dose-related side effects. By
delaying absorption oftocainide, a snack could blunt a sharp
increase in peak serum concentration without altering the
total bioavailability (9). In some patients, tocainide was
given every 6 hours rather than every 8 hours to further
minimize dose-related side effects. Other investigators (22)
also used shorter dosing intervals to lessen dose-related side
effects of mexiletine. By giving the same total daily dosage
of a drug in smaller and more frequent doses, one may avoid
the sharp increase in serum drug concentration and dose-
related side effects seen after administrations of larger doses
of the drug given at less frequent intervals.
Combination therapy. Tocainide and quinidine have
different side effects (9-11). Therefore, combination of to-
cainide and quinidine may render additive antiarrhythmic
effects without additive side effects. The results of our study
support this assumption. The combination of different anti-
arrhythmic agents has been reported on by several inves-
tigators (11,18,22,23). Duff et al. (22) reported enhanced
efficacy and reduction of dose-related side effects of mex-
iletine when combined with quinidine. Our results suggest
that efficacy and tolerance of tocainide also improve when
it is combined with quinidine. Although mexiletine and
tocainide are congeners of lidocaine with similar electro-
physiologic effects, Hession et al. (24) recently reported
that the two agents have different clinical effects and each
agent should be evaluated individually. No other investi-
gators have studied the combination of tocainide and quin-
idine.
Duff et al. (22) reported that addition of mexiletine to
quinidine shortens the quinidine-induced increase in QTc
interval. In our study, the durations of the QRS complex
and QTc interval during combination therapy were signif-
icantly shorter than those during quinidine alone. However,
because the dosage of quinidine was less during combination
therapy, one cannot determine from our study if tocainide
has any influences on the quinidine-induced increase in QRS
duration and QTc interval.
Clinical implications. A significant number of patients
develop dose-related side effects from quinidine or tocainide
administered in doses that achieve plasma levels adequate
for arrhythmia suppressions (8,22). When the dose of the
drug is reduced, the arrhythmias often recur (8). Our study
suggests that a combination of smaller and well tolerated
dosages of quinidine and tocainide may be useful in such
situations. Combination of the two agents in smaller doses,
although they may be subtherapeutic when used individ-
ually, may render therapeutic effects.
When the maximal dosage of one agent (for example,
1,600 mg/day of quinidine or 2,400 mg/day of tocainide in
our study) is well tolerated without side effects but is in-
effective, further increase in the dose may cause adverse
cardiac side effects such as an excessive prolongation of the
QTc interval and torsade de pointes from quinidine (25). In
this situation, a combination of the maximal dosage of quin-
idine and the maximal or submaximal dosage of tocainide
may be safer and more effective compared with giving more
than the customarily used maximal dosage of quinidine.
Others (26) have reported that a combination of the maximal
dose of mexiletine and the maximal dose of quinidine is
safe and effective. In our study, however, less quinidine
and tocainide were used during the combination therapy.
Therefore, the assumption regarding safety and efficacy of
combining the two agents in the maximal dosage remains
to be tested.
Our patients had coronary artery disease and frequent
(2':30/h) ventricular premature complexes. No patient had
significant congestive heart failure before drug therapy. The
results of our study may not be applicable to other patient
groups. In addition, our study included acute drug testing
using 24 hour Holter monitoring. Long-term follow-up stud-
ies will be necessary to determine the long-term effects of
the combination therapy.
We express appreciation to Lawrence Krasnoff for assistance in the sta-
tistical analysis and to Patti Garcia for secretarial assistance in the manu-
script preparation.
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